MDM2 Is a Useful Prognostic Biomarker for Resectable Gastric Cancer

Cancer Science - United States
doi 10.1111/cas.12111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Targeted Proteomics Approach Reveals a Serum Protein Signature as Diagnostic Biomarker for Resectable Gastric Cancer

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

PD-L1 Expression Combined With Microsatellite Instability/Cd8+ Tumor Infiltrating Lymphocytes as a Useful Prognostic Biomarker in Gastric Cancer

Scientific Reports
Multidisciplinary
2019English

Clinicodemographic Aspect of Resectable Pancreatic Cancer and Prognostic Factors for Resectable Cancer

World Journal of Surgical Oncology
SurgeryOncology
2012English

Comment on “circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer”

Disease Markers
BiochemistryMedicineClinical BiochemistryMolecular BiologyGenetics
2019English

Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker

Cancers
Cancer ResearchOncology
2019English

Angiopoietin-Like Protein 2 Is a Potential Biomarker for Gastric Cancer

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2014English

EphA4 Is a Prognostic Factor in Gastric Cancer

BMC Clinical Pathology
Forensic MedicinePathologyHistology
2013English

Identification of F5 as a Prognostic Biomarker in Patients With Gastric Cancer

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2020English

Mean Platelet Volume Provides Beneficial Diagnostic and Prognostic Information for Patients With Resectable Gastric Cancer

Oncology Letters
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy